Boundless Bio, Inc.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Arrangements
From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into or terminate Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended June 30, 2025, our officers or directors adopted, modified, or terminated such trading arrangements as set forth below.
| Action · Date · Trading Arrangement | |||||
|---|---|---|---|---|---|
| Rule 10b5-1* · Non-Rule 10b5‑1** · Total Shares Subject to Plan · Expiration Date | |||||
| Robert Doebele, MD, Ph.D. Chief Medical Officer | Adopted | April 3, 2025 | X | 45,000 | August 3, 2026 |
| ____________________* Intended to satisfy the affirmative defense of Rule 10b5-1(c)** Not intended to satisfy the affirmative defense of Rule 10b5-1(c) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.